RT Journal Article
SR Electronic
T1 Indolent Presentations of Leukemic Lung Disease in Acute Myeloid Leukemia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.12.20211276
DO 10.1101/2020.10.12.20211276
A1 Yukiko Kunitomo
A1 Seohyuk Lee
A1 Chace C. Avery
A1 Patricia L. Valda Toro
A1 Avi J. Cohen
A1 Solmaz Ehtashimi-Afshar
A1 Peter A. Kahn
A1 Alexa Siddon
A1 Prajwal Boddu
A1 Rupak Datta
A1 Charles S. Dela Cruz
A1 Samir Gautam
YR 2020
UL http://medrxiv.org/content/early/2020/10/14/2020.10.12.20211276.abstract
AB Background Patients with active acute myelogenous leukemia (AML) are at risk for leukemic infiltration (LI) into the lung and acute tumor lysis pneumopathy (ATLP) following chemotherapy. Fulminant presentations of these leukemic lung diseases are well-described, but indolent forms have not yet been studied. Therefore, we sought to elucidate the clinical features of mild-to-moderate LI and ATLP.Methods A retrospective cohort analysis was performed on 51 hospitalized patients with AML, circulating blast count ≥3%, non-critical illness, and receipt of bronchoscopy between 2015-2019. Diagnoses of LI and ATLP were made via retrospective chart review by a multidisciplinary team of physicians.Results 19 cases of leukemic lung disease were identified: 14 with LI and 5 with ATLP. The clinical presentations closely resembled pneumonia, with the majority demonstrating respiratory symptoms (63%), hypoxemia (63%), fever (84%), and pulmonary opacities (100%). All patients were presumptively diagnosed with infection, leading to an average of 18 days of broad-spectrum antibiotic therapy and multiple instances of delayed chemotherapy in treatment candidates. Although most patients were near the end-of-life (90% died within 1 year), transitions to comfort care were infrequent (25%) and hospitalizations were protracted (median 25 days).Conclusions LI and ATLP are common yet under-recognized pulmonary complications in patients with active AML. When presenting indolently, these conditions are difficult to distinguish from lung infection, leading to missed diagnosis, inappropriate antibiosis, chemotherapy deferrals, and prolonged hospitalizations. Greater awareness and consensus definitions of LI and ATLP are therefore needed to improve care of this population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementT32 (T32-HL007778) and F32 (1F32HL154641-01) to Samir Gautam; T32 (2T32AI007517-16) to Rupak Datta; VA Merit award (BX004661), DOD grant (PR181442), and U19 (AI089992-09S2) to Charles Delacruz. There was no non-grant third party funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yale Institutional Review Board #2000022465All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified data related to this study is available upon request addressed to the corresponding author (samir.gautam@yale.edu)